Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

Published:2013-11-04 Issue:2 Volume:164 Page:223-232
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Deininger Michael W.¹,Kopecky Kenneth J.²³,Radich Jerald P.³,Kamel-Reid Suzanne⁴,Stock Wendy⁵,Paietta Elisabeth⁶,Emanuel Peter D.⁷,Tallman Martin⁸,Wadleigh Martha⁹,Larson Richard A.⁵,Lipton Jeffrey H.¹⁰,Slovak Marilyn L.¹¹,Appelbaum Frederick R.³,Druker Brian J.¹

Affiliation:

1. Oregon Health and Science University; Portland OR USA

2. SWOG Statistical Center; Seattle WA USA

3. Fred Hutchinson Cancer Research Center; Seattle WA USA

4. Ontario Cancer Institute/Princess Margaret Hospital; Toronto ON Canada

5. University of Chicago; Chicago IL USA

6. Montefiore Medical Center; Bronx NY USA

7. University of Arkansas for Medical Sciences; Little Rock AR USA

8. Memorial Sloan Kettering Cancer Center; New York NY USA

9. Dana Farber Cancer Institute; Boston MA USA

10. University Health Network-OCI/Princess Margaret Hospital; Toronto ON Canada

11. City of Hope; Duarte CA USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.12618/fullpdf

Reference30 articles.

1. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;Journal of Clinical Oncology,2009a

2. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study;Baccarani;Blood,2009b

3. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party;Castagnetti;Blood,2009

4. High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses;Cortes;Journal of Clinical Oncology,2009

5. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study;Cortes;Journal of Clinical Oncology,2010

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Population modeling of bosutinib exposure‐response in patients with newly diagnosed chronic phase chronic myeloid leukemia;Cancer Medicine;2023-08-08

2. Update in Childhood Chronic Myeloid Leukemia;Hemato;2022-11-05

3. Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience;Pharmacology Research & Perspectives;2022-09-14

4. Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia;Pharmaceutics;2022-08-12

5. Use of copula to model within‐study association in bivariate meta‐analysis of binomial data at the aggregate level: A Bayesian approach and application to surrogate endpoint evaluation;Statistics in Medicine;2022-08-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3